Ponatinib (AP24534)

Name: Ponatinib (AP24534)
Brand: Selleck Chemicals
SKU: S1490
Rating: 5 (120 reviews)

For research use only.

Catalog No.S1490

120 publications

CAS No. 943319-70-8

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively. Ponatinib (AP24534) inhibits autophagy.

Selleck's Ponatinib (AP24534) has been cited by 120 publications

Nature, 2020, 583(7818):845-851

PubMed: 32699415 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4370

PubMed: 32873792 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.32924

PubMed: 32064608 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

J Infect Dis, 2020, 3;jiaa295

PubMed: 32492702 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 30;11:543

PubMed: 32425788 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):592

PubMed: 32580713 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Nature, 2020, 583(7818):845-851

PubMed: 32699415 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:408

PubMed: 32596239 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020, 1;6(2) pii: a004838

PubMed: 31980503 ( click the link to review the publication )
Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0217451

PubMed: 31682640 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Hemasphere, 2019, 3(2):e182

PubMed: 31723821 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Br J Haematol, 2018, 181(5):642-652

PubMed: 29675955 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5596-5606

PubMed: 30160357 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncotarget, 2018, 9(62):31958-31970

PubMed: 30174789 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(78):34735-34747

PubMed: 30410673 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

ChemMedChem, 2017, 12(16):1390-1398

PubMed: 28639308 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(16):26613-26624

PubMed: 28460451 ( click the link to review the publication )
Oncotarget, 2017, 8(40):67709-67722

PubMed: 28978065 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Blood, 2016, 28;127(17):2131-43

PubMed: 26864341 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(3):1139-50

PubMed: 26933192 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )
Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1168-81

PubMed: 25015643 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M2rpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMECwNFAxODN3OTFOwG0>	M3OzbHNCVkeHUh?=
MV-4-11	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjsfVFKSzVyPUCuNFAxODl3NjFOwG0>	MljqV2FPT0WU
MEG-01	M372W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzrU2pKSzVyPUCuNFAxOTJ6IN88US=>	Mm\ZV2FPT0WU
LAMA-84	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofPTWM2OD1yLkCwNFE3PSEQvF2=	M1fpd3NCVkeHUh?=
CGTH-W-1	NGrFVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjxPGJCUUN3ME2wMlAxOTZ7IN88US=>	NV3YeW5yW0GQR1XS
KASUMI-1	NWnrV4R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXFXYpKSzVyPUCuNFAzOTdizszN	NGK2PGtUSU6JRWK=
BE-13	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMECyOVkh\|ryP	NX:1SmQ1W0GQR1XS
CTV-1	M3HKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET4OlRKSzVyPUCuNFA2OjFizszN	MY\TRW5ITVJ?
NKM-1	NFzD[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;nZpVKSzVyPUCuNFA3PTVizszN	MYHTRW5ITVJ?
MONO-MAC-6	NYjxTo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7SdFhKSzVyPUCuNFA5OzdizszN	MWjTRW5ITVJ?
A204	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XvNmlEPTB;MD6wNVIyQCEQvF2=	NUO0XlZ3W0GQR1XS
GDM-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS1TWM2OD1yLkCxPFM{KM7:TR?=	Mmn6V2FPT0WU
AN3-CA	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMEG4O\|Mh\|ryP	NISyOGdUSU6JRWK=
BL-70	NF7kWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjWTWM2OD1yLkCyNVk6KM7:TR?=	NHnJTnJUSU6JRWK=
Daudi	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHTTWM2OD1yLkCyOVM4KM7:TR?=	NXrYcmZjW0GQR1XS
KU812	NIjBWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMEK4OFgh\|ryP	MXrTRW5ITVJ?
KG-1	M2SzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LId2lEPTB;MD6wN\|I6PCEQvF2=	NU\wbJpzW0GQR1XS
DOHH-2	NVy4dZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHpTWM2OD1yLkC0PFA{KM7:TR?=	MYXTRW5ITVJ?
HuO9	NFrNUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon6TWM2OD1yLkC1OFQ5KM7:TR?=	MmnoV2FPT0WU
EB2	NGDsN\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLiPI1KSzVyPUCuNFU2PzZizszN	MYHTRW5ITVJ?
G-402	NGTrSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nENGlEPTB;MD6wOlM1OSEQvF2=	NVTFV5A2W0GQR1XS
SU-DHL-1	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPEflNtUUN3ME2wMlA3Ozd7IN88US=>	M33WVHNCVkeHUh?=
NCI-H719	M2DpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\scYJKSzVyPUCuNFc5QDhizszN	NWXCU2FEW0GQR1XS
MLMA	M{XKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDHTWM2OD1yLkC5NFYh\|ryP	MlLKV2FPT0WU
KM12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2q5OmlEPTB;MD6wPVc{PyEQvF2=	M3jpUXNCVkeHUh?=
SUP-T1	NFe4dlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XmSWlEPTB;MD6wPVk5OiEQvF2=	NEewN\|lUSU6JRWK=
MZ1-PC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMUGzN\|Yh\|ryP	M1j3enNCVkeHUh?=
MFE-296	M2nLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\3dmlEPTB;MD6xNVg{QSEQvF2=	M{HwW3NCVkeHUh?=
ALL-PO	NXS1V\|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DqRmlEPTB;MD6xNlQ1OyEQvF2=	MVPTRW5ITVJ?
GB-1	NWHqfmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlyyTWM2OD1yLkGyOVEzKM7:TR?=	MVXTRW5ITVJ?
SIG-M5	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInFZYpKSzVyPUCuNVM{PyEQvF2=	NHjlNotUSU6JRWK=
P30-OHK	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFL5fFlKSzVyPUCuNVU3PzJizszN	MYXTRW5ITVJ?
NCI-H716	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PwVGlEPTB;MD6xOlI3PiEQvF2=	M17CO3NCVkeHUh?=
MPP-89	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfRcFFMUUN3ME2wMlE3QTN\|IN88US=>	MYrTRW5ITVJ?
SF126	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nOUWlEPTB;MD6xO\|A3OyEQvF2=	M2DPbnNCVkeHUh?=
CTB-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMUezNVYh\|ryP	MX3TRW5ITVJ?
CA46	NIDnSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMUe0PFkh\|ryP	NWfoZXhOW0GQR1XS
NCI-H520	NGD5SZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknuTWM2OD1yLkG3O\|MzKM7:TR?=	MmS0V2FPT0WU
CAL-85-1	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzvTWM2OD1yLkG3PVI4KM7:TR?=	NInn[3FUSU6JRWK=
NCI-H2342	M{L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3G5fWlEPTB;MD6xPFU4PyEQvF2=	M3TsbHNCVkeHUh?=
697	NWHTRpVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z6dGlEPTB;MD6xPFg4OSEQvF2=	NI\XT2JUSU6JRWK=
NY	NVHrTZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrKRlFKSzVyPUCuNVkzQDdizszN	M3\kR3NCVkeHUh?=
T98G	NH6wS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fXSGlEPTB;MD6xPVMyQCEQvF2=	NYnHRoM3W0GQR1XS
NCI-H1703	NFLyc\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMUm2NVUh\|ryP	NF7sO\|dUSU6JRWK=
NCI-H2087	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMkC0N\|kh\|ryP	M2\nbXNCVkeHUh?=
PF-382	NF:2N5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\SfWdKSzVyPUCuNlA5PzNizszN	MV\TRW5ITVJ?
HCT-116	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnNTWM2OD1yLkKxNFY6KM7:TR?=	MmLQV2FPT0WU
CAKI-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTTSYtUUUN3ME2wMlIyPjZ4IN88US=>	MoO1V2FPT0WU
CCF-STTG1	NV:1O2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nne2lEPTB;MD6yNlQ4PSEQvF2=	MXHTRW5ITVJ?
D-392MG	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfLTWM2OD1yLkKzNVc4KM7:TR?=	MYrTRW5ITVJ?
RT-112	NYX4dm1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMkO3PVUh\|ryP	Ml;lV2FPT0WU
MES-SA	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HTdGlEPTB;MD6yOFE5PyEQvF2=	MX\TRW5ITVJ?
LC-2-ad	NWrUPXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPURYRtUUN3ME2wMlI1OjZ3IN88US=>	NUTYZW1iW0GQR1XS
NOS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoL5TWM2OD1yLkK0N\|Y4KM7:TR?=	NUW4TnhpW0GQR1XS
NALM-6	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe4VXkxUUN3ME2wMlI2PTR\|IN88US=>	NFfO[HVUSU6JRWK=
TE-15	NHy2NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HqN2lEPTB;MD6yOlA6OSEQvF2=	MkjSV2FPT0WU
786-0	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPGbXA3UUN3ME2wMlI3OjJ6IN88US=>	MYTTRW5ITVJ?
IST-MES1	NUfk[pV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTrfYhKSzVyPUCuNlY5OjlizszN	NHO3cHpUSU6JRWK=
KYSE-180	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfzXW82UUN3ME2wMlI3QDlzIN88US=>	NXHSUHRzW0GQR1XS
YT	NF;1ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfqUG94UUN3ME2wMlI3QTd2IN88US=>	M3rjZXNCVkeHUh?=
A427	M4rpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP4N2dKSzVyPUCuNlczPjRizszN	MVHTRW5ITVJ?
KYSE-450	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDUTWM2OD1yLkK3N\|I6KM7:TR?=	MnnHV2FPT0WU
HuH-7	M1fnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMke3OlMh\|ryP	NEi2T\|BUSU6JRWK=
CAS-1	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkewTWM2OD1yLkK4N\|A{KM7:TR?=	MULTRW5ITVJ?
KURAMOCHI	NYnKOpRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;Wb2lEPTB;MD6yPFQyQSEQvF2=	M1fKenNCVkeHUh?=
ACHN	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW[1T2s6UUN3ME2wMlI6OzJ\|IN88US=>	MmDGV2FPT0WU
HGC-27	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEntNY1KSzVyPUCuNlk{PTNizszN	NG\sbZBUSU6JRWK=
A172	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMkm1O\|ch\|ryP	MmKyV2FPT0WU
SNU-449	NUDCZY5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnoV\|NuUUN3ME2wMlI6QTZ2IN88US=>	MUnTRW5ITVJ?
SW982	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMkm5O\|gh\|ryP	NHvXPYxUSU6JRWK=
EFO-21	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwM{C0NVEh\|ryP	NYf4[ZZtW0GQR1XS
NCI-H2030	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLETWM2OD1yLkOxNVY1KM7:TR?=	MmroV2FPT0WU
HT-144	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHyxOWlKSzVyPUCuN\|EzQCEQvF2=	M{C1fXNCVkeHUh?=
MFE-280	NFjHOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{foRWlEPTB;MD6zNVQ2OyEQvF2=	M4rqTHNCVkeHUh?=
SK-LU-1	M1z6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3K4PWlEPTB;MD6zNVQ3PiEQvF2=	Mk[0V2FPT0WU
NCI-H2052	M1;MfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwM{G0PFQh\|ryP	M2Xqb3NCVkeHUh?=
SK-HEP-1	NFrWNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\R[\|BKSzVyPUCuN\|M{PjhizszN	NFTUZ\|RUSU6JRWK=
QIMR-WIL	M1TUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT1TWM2OD1yLkOzOFI1KM7:TR?=	M2XGVXNCVkeHUh?=
A2780	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwM{SzNFQh\|ryP	M4HaWHNCVkeHUh?=
ACN	M2D5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vjZ2lEPTB;MD6zOFg4OyEQvF2=	M4XjVHNCVkeHUh?=
BxPC-3	NVPDcVJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rSSGlEPTB;MD6zOFk5QSEQvF2=	NYf4[VJVW0GQR1XS
BCPAP	M2jHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\WOlh2UUN3ME2wMlM3ODBzIN88US=>	NU\Cd4t5W0GQR1XS
HOP-62	M4fQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXL5PYU5UUN3ME2wMlM3OTB4IN88US=>	MYDTRW5ITVJ?
SW1710	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LnO2lEPTB;MD6zOlQ2PSEQvF2=	M2jPRnNCVkeHUh?=
OPM-2	NWqyUVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPQTYVPUUN3ME2wMlM3PDd\|IN88US=>	M4i3WHNCVkeHUh?=
DBTRG-05MG	NFv1SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwM{iwOVQh\|ryP	NH7hRYZUSU6JRWK=
SK-MEL-24	NULXSolWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfBXFd2UUN3ME2wMlM6PzlzIN88US=>	MnvoV2FPT0WU
8305C	NXO1XmxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;jTWM2OD1yLkO5O\|k{KM7:TR?=	MW\TRW5ITVJ?
OVCAR-4	NHO1eXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjoTJJKSzVyPUCuOFE2QDZizszN	NXf5cHo4W0GQR1XS
HLE	NWrEflRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHe2OWxKSzVyPUCuOFE5PiEQvF2=	NHTkcWxUSU6JRWK=
NCI-H747	NGezU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfEW3hKSzVyPUCuOFIyOzdizszN	NWfOd\|czW0GQR1XS
SW780	NHe3cVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwNEKzOFYh\|ryP	NGTTU\|RUSU6JRWK=
KYSE-150	NHrjNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwNEK0NVUh\|ryP	NFHjcohUSU6JRWK=
H4	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\hfYhKSzVyPUCuOFI1PTFizszN	MXXTRW5ITVJ?
SW1088	M1e4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4e5V2lEPTB;MD60OFM6KM7:TR?=	NXGxWoFCW0GQR1XS
SF268	NU\ZfHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHFS3VKSzVyPUCuOFQ5PiEQvF2=	NXzFeFIxW0GQR1XS
RT4	NFjvd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDTTWM2OD1yLkS1NVEyKM7:TR?=	MUnTRW5ITVJ?
NCI-H522	NHnROpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz2NWNKSzVyPUCuOFUzPyEQvF2=	NIP6fWlUSU6JRWK=
LCLC-97TM1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HPdmlEPTB;MD60OlE6PSEQvF2=	M1TvSHNCVkeHUh?=
CAL-39	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TKWGlEPTB;MD60OlUyQSEQvF2=	MUHTRW5ITVJ?
CAL-120	NHTlNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnixTWM2OD1yLkS3OlQ{KM7:TR?=	NUG4OXhCW0GQR1XS
ESS-1	NWPIOI5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjvTWM2OD1yLkS3PFIyKM7:TR?=	MVnTRW5ITVJ?
KARPAS-45	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;lTWM2OD1yLkS4PVM{KM7:TR?=	NWPLSppPW0GQR1XS
DU-4475	NEPzUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TPWGlEPTB;MD60PVUyOSEQvF2=	M{\kXHNCVkeHUh?=
VMRC-RCZ	NIDmO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDNTWM2OD1yLkS5PVA1KM7:TR?=	NHK3TXhUSU6JRWK=
HOS	M{Lqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\ITWM2OD1yLkWwN\|Y2KM7:TR?=	MlrVV2FPT0WU
MOLT-16	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3HdYZKSzVyPUCuOVE5ODhizszN	MXfTRW5ITVJ?
RPMI-6666	M33u[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rVVGlEPTB;MD61NlE{PSEQvF2=	MVPTRW5ITVJ?
K052	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrpSlBGUUN3ME2wMlUzOTRizszN	NFXxOnhUSU6JRWK=
EHEB	M1iwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mxTWlEPTB;MD61NlE5OiEQvF2=	M1GybHNCVkeHUh?=
MFH-ino	M2jhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfHWGNKSzVyPUCuOVI{PTFizszN	NUXBPHBPW0GQR1XS
A4-Fuk	NXm3NlNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXewUIMxUUN3ME2wMlUzPTJ6IN88US=>	MniyV2FPT0WU
SW1417	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwNUK3PFEh\|ryP	MlrDV2FPT0WU
DoTc2-4510	NF3mPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLnTWM2OD1yLkW0PVU5KM7:TR?=	NWHkcIx{W0GQR1XS
TE-12	M3XwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHlTWM2OD1yLkW1O\|M2KM7:TR?=	NFPIbJJUSU6JRWK=
8-MG-BA	NFeyZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnW4TWM2OD1yLkW2NFU3KM7:TR?=	NVfzZ3FYW0GQR1XS
ECC12	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwNU[1OVgh\|ryP	MWfTRW5ITVJ?
CHL-1	MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWqwPJh[UUN3ME2wMlU4PDZ\|IN88US=>	NYPOWHBtW0GQR1XS
LCLC-103H	NGG5ZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjOTWM2OD1yLkW4N\|Q1KM7:TR?=	MUfTRW5ITVJ?
OS-RC-2	M3H4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwNUizO\|kh\|ryP	MmqxV2FPT0WU
RO82-W-1	M{fMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDPTWM2OD1yLkW5OlE2KM7:TR?=	MWXTRW5ITVJ?
A3-KAW	NWD3[4YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwNkG0Olch\|ryP	NGTIO4JUSU6JRWK=
NCCIT	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW5TWM2OD1yLk[xO\|E2KM7:TR?=	M3ryenNCVkeHUh?=
IST-SL2	M3jJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:1TWM2OD1yLk[yOVIzKM7:TR?=	MkTlV2FPT0WU
GI-ME-N	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjOU4FKSzVyPUCuOlMxPjlizszN	MlvXV2FPT0WU
ES6	NF72V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW3XlE4UUN3ME2wMlY{Ojl3IN88US=>	NV3PTZBZW0GQR1XS
BL-41	M{TtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwNkOzOVIh\|ryP	NV7OPIhZW0GQR1XS
Ca-Ski	NYDUSYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;3TmlEPTB;MD62OFgyKM7:TR?=	Mn\LV2FPT0WU
HOP-92	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS2PVUyUUN3ME2wMlY2Pjd{IN88US=>	Mm\oV2FPT0WU
SK-LMS-1	NGPxfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTFUlk2UUN3ME2wMlY3PDdizszN	NIHKSXhUSU6JRWK=
EW-13	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnsSHJbUUN3ME2wMlY3Pzd7IN88US=>	M3HKZ3NCVkeHUh?=
647-V	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwNkixOFgh\|ryP	NYXtbIJrW0GQR1XS
JiyoyeP-2003	NFHDUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PHXGlEPTB;MD62PVc{QCEQvF2=	M365UHNCVkeHUh?=
WSU-NHL	M3HYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLRTWM2OD1yLkewPFg4KM7:TR?=	MkOzV2FPT0WU
U-698-M	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn5[FdNUUN3ME2wMlcyODZ\|IN88US=>	NYX6[mRtW0GQR1XS
HC-1	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwN{K0NFUh\|ryP	NID6U2pUSU6JRWK=
8505C	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K1[2lEPTB;MD63Nlc1OSEQvF2=	MY\TRW5ITVJ?
HUTU-80	NE[4THRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvqTWM2OD1yLkezN\|Q6KM7:TR?=	NGO2bmVUSU6JRWK=
LB1047-RCC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXwPGdKSzVyPUCuO\|M2OzhizszN	NHr3UolUSU6JRWK=
GAMG	NVPze2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn5b\|FoUUN3ME2wMlc{PjV\|IN88US=>	Mn22V2FPT0WU
CAL-12T	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\rTlVEUUN3ME2wMlc{QDd5IN88US=>	NYfx[WdMW0GQR1XS
NCI-SNU-1	NIS1bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLTTWM2OD1yLke3Nlc5KM7:TR?=	M3zjb3NCVkeHUh?=
HTC-C3	NFrxUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C0ZWlEPTB;MD63O\|Q2OSEQvF2=	MV\TRW5ITVJ?
HPAF-II	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwN{e1NFEh\|ryP	MWrTRW5ITVJ?
KGN	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzkNXRKSzVyPUCuO\|gxQDFizszN	MYHTRW5ITVJ?
EFO-27	MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\UT2lEPTB;MD63PFc{OyEQvF2=	NUDZUXQ3W0GQR1XS
MEL-HO	NG\4WYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\KbGtEUUN3ME2wMlc6PDR7IN88US=>	MmDSV2FPT0WU
KYSE-270	NGH1NZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrue5BKSzVyPUCuPFA2OjlizszN	NVPqcZhKW0GQR1XS
NCI-H1755	NWTZb5ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkW4TWM2OD1yLkiwO\|E1KM7:TR?=	NWrjd4t4W0GQR1XS
MFM-223	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwOEG0NFch\|ryP	MWfTRW5ITVJ?
G-361	M{nJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLLTWM2OD1yLkixPFk4KM7:TR?=	M{nTRnNCVkeHUh?=
ETK-1	NFTwe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwOEK0OFEh\|ryP	NI\p[oRUSU6JRWK=
LU-99A	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XNN2lEPTB;MD64OFcxOSEQvF2=	M1q3NnNCVkeHUh?=
IST-MEL1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorxTWM2OD1yLki1O\|MzKM7:TR?=	MXPTRW5ITVJ?
L-540	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrIUYtKSzVyPUCuPFU5ODFizszN	NHXyZZJUSU6JRWK=
U-2-OS	NV;zWmdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\mUXZKSzVyPUCuPFU5PDZizszN	NIjBTXVUSU6JRWK=
HT-1376	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPLTWM2OD1yLki2NFUyKM7:TR?=	MV\TRW5ITVJ?
COLO-680N	M4PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\LTWM2OD1yLki3PVM{KM7:TR?=	MXLTRW5ITVJ?
NCI-H1581	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[0R2lEPTB;MD64PVI6PyEQvF2=	MlewV2FPT0WU
HuCCT1	MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnqdYhKSzVyPUCuPFk2PDhizszN	MnrvV2FPT0WU
BB30-HNC	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\jTWM2OD1yLkmyOFY6KM7:TR?=	MlTkV2FPT0WU
NCI-H2347	M1TTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTMOoRKSzVyPUCuPVMzQTJizszN	M2H6cHNCVkeHUh?=
G-401	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfNXXQ2UUN3ME2wMlk{Pjl3IN88US=>	NEnxbWVUSU6JRWK=
NCI-H358	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XrbmlEPTB;MD65OVAyPCEQvF2=	MXPTRW5ITVJ?
HCC1395	Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXrPFBKSzVyPUCuPVU1PjFizszN	M1[2U3NCVkeHUh?=
J82	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\oUmlEPTB;MD65OVU1OyEQvF2=	Mnv5V2FPT0WU
KE-37	NE\KbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nmRmlEPTB;MD65OlM5PyEQvF2=	NIjFdZhUSU6JRWK=
NOMO-1	NX;KTFJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnX6TWM2OD1yLkm2OVY1KM7:TR?=	MVHTRW5ITVJ?
ML-2	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHvTWM2OD1yLkm5O\|Uh\|ryP	M4S1TnNCVkeHUh?=
SW872	M3LzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHZTWM2OD1yLkm5O\|c2KM7:TR?=	NUXr[m9wW0GQR1XS
KYSE-520	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7sUZlKSzVyPUGuNFA1QTRizszN	MorQV2FPT0WU
HL-60	NGOzb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHNUpl6UUN3ME2xMlAxQTdizszN	NFTpPYJUSU6JRWK=
HDLM-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnlTWM2OD1zLkCxNlUzKM7:TR?=	Mm\nV2FPT0WU
MIA-PaCa-2	NWW3PIxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\LUVNNUUN3ME2xMlAyOzd3IN88US=>	NXXxeZBqW0GQR1XS
TCCSUP	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3JTWM2OD1zLkCxO\|MzKM7:TR?=	M3ywN3NCVkeHUh?=
SH-4	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLsTWM2OD1zLkCyNlQ1KM7:TR?=	M1XDV3NCVkeHUh?=
MG-63	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;XbGlEPTB;MT6wNlYyPiEQvF2=	NFOybYVUSU6JRWK=
NB6	NVHQZW03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTFwMEOxNFkh\|ryP	NWf5bXNKW0GQR1XS
CAL-54	NXjwXms3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwMEO5OVkh\|ryP	MULTRW5ITVJ?
DU-145	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTFwMEiwO\|Mh\|ryP	MWjTRW5ITVJ?
HCE-4	M3;WZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn2yTWM2OD1zLkC5Nlg3KM7:TR?=	MnPHV2FPT0WU
U-266	M4nUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXPTWM2OD1zLkC5OlM{KM7:TR?=	M17TPHNCVkeHUh?=
HT-1197	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\0UpY1UUN3ME2xMlEyPDN6IN88US=>	M4n1dnNCVkeHUh?=
EW-1	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrsZ5RKSzVyPUGuNVQyOjhizszN	NF7t[o9USU6JRWK=
MHH-NB-11	NHixSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwMUWzOlgh\|ryP	NIq5S\|lUSU6JRWK=
NCI-H2405	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofNTWM2OD1zLkG2NVYh\|ryP	M2[4[HNCVkeHUh?=
COLO-668	M1XIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPRTWM2OD1zLkG2OFkh\|ryP	MYHTRW5ITVJ?
IMR-5	M3zlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfkT\|ZoUUN3ME2xMlE3QTN4IN88US=>	MVXTRW5ITVJ?
ARH-77	M3LuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37G[2lEPTB;MT6yNlkzPCEQvF2=	NVrQTZBwW0GQR1XS
BHT-101	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3yeoFKSzVyPUGuNlM1QSEQvF2=	MlrjV2FPT0WU
SCC-25	NUDBc\|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTFwMkO1N\|Yh\|ryP	MVXTRW5ITVJ?
NTERA-S-cl-D1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1joUGlEPTB;MT6yOFM1PiEQvF2=	NF3EWWdUSU6JRWK=
MKN28	NIPlPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTFwMkW2N\|Yh\|ryP	M3vsXHNCVkeHUh?=
KS-1	NWft[pBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnJ[5BKSzVyPUGuNlgzPjlizszN	MnXZV2FPT0WU
NCI-H1734	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvGSlhKSzVyPUGuNlg6OTNizszN	MmjYV2FPT0WU
ES7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTFwMkm1OFIh\|ryP	NH3qbZVUSU6JRWK=
NCI-H838	M1LCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkmyTWM2OD1zLkOwOlE2KM7:TR?=	MmjrV2FPT0WU
HEC-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEK5NY1KSzVyPUGuN\|M4PTVizszN	NGW5XVNUSU6JRWK=
ME-180	M3XOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfqbphKSzVyPUGuN\|c6QTNizszN	MVzTRW5ITVJ?
MMAC-SF	NU\SOZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rJdmlEPTB;MT6zPVU6PSEQvF2=	NFrWOnRUSU6JRWK=
IA-LM	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLFcWlKSzVyPUGuOFA6OTRizszN	MX3TRW5ITVJ?
MN-60	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPZTWM2OD1zLkSzNVE1KM7:TR?=	NGn1bXFUSU6JRWK=
SIMA	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTFwNEi2PFch\|ryP	NWDoW4d{W0GQR1XS
NCI-H1770	NVL4d2FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkH1TWM2OD1zLkWyNFU1KM7:TR?=	M3PIVXNCVkeHUh?=
ONS-76	NV\qO2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4P5XmlEPTB;MT61NlMyOSEQvF2=	M2LNUHNCVkeHUh?=
LB771-HNC	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjVeWo6UUN3ME2xMlU{QTB4IN88US=>	NIn0R\|JUSU6JRWK=
SW48	NHPjOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTFwNUSyOFMh\|ryP	M{\iOnNCVkeHUh?=
KYSE-140	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFwNUW3OFEh\|ryP	NULmeIVtW0GQR1XS
SW626	NV;WO2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXCTWM2OD1zLkW4NVYh\|ryP	NUPsNmI6W0GQR1XS
MC-CAR	M1HCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml21TWM2OD1zLkW4OlY{KM7:TR?=	M3XSW3NCVkeHUh?=
D-336MG	NVfiOY5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP2dXF[UUN3ME2xMlYzQTRizszN	MYLTRW5ITVJ?
SK-MEL-3	NIH1[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPkUYVVUUN3ME2xMlY{QTB{IN88US=>	MWrTRW5ITVJ?
MHH-PREB-1	M1nke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3frO2lEPTB;MT62OFQ4OyEQvF2=	NYnJTVl[W0GQR1XS
Calu-1	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfWTWM2OD1zLk[1N\|g3KM7:TR?=	MmDvV2FPT0WU
HCC1806	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTFTWM2OD1zLk[2OlEyKM7:TR?=	MkHoV2FPT0WU
A101D	NH;JOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vmfWlEPTB;MT62Olc5OSEQvF2=	MXfTRW5ITVJ?
A704	M2jQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFwNkizNVEh\|ryP	MXTTRW5ITVJ?
LB831-BLC	M{OxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2L0RWlEPTB;MT62PVg2PCEQvF2=	MnjVV2FPT0WU
RL95-2	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PPbGlEPTB;MT63NVQ3OyEQvF2=	NFjLVGNUSU6JRWK=
RPMI-2650	M3XFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfMTWM2OD1zLkeyO\|E6KM7:TR?=	MV7TRW5ITVJ?
NH-12	NWPqS5ptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVr0SHNsUUN3ME2xMlc{PDJ5IN88US=>	MU\TRW5ITVJ?
AGS	NIDrfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXlTWM2OD1zLke2N\|U5KM7:TR?=	NHzRRmlUSU6JRWK=
NEC8	NYXvZ5VxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\ae5lKSzVyPUGuO\|g6QTVizszN	M4DDXXNCVkeHUh?=
NCI-H2009	NUjWOVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnVUWJHUUN3ME2xMlc6PzJzIN88US=>	MV3TRW5ITVJ?
A498	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XKU2lEPTB;MT64NVI5OiEQvF2=	MU\TRW5ITVJ?
NCI-H810	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHCWJNQUUN3ME2xMlgyPjB4IN88US=>	NE\1SY1USU6JRWK=
SK-NEP-1	NGfmUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O3T2lEPTB;MT64N\|c3PyEQvF2=	M4e4SnNCVkeHUh?=
D-542MG	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXviOVFVUUN3ME2xMlg2QDVzIN88US=>	Mkn4V2FPT0WU
KNS-42	NVXRZ\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnXRnk{UUN3ME2xMlg3OjZ4IN88US=>	MWDTRW5ITVJ?
NCI-H2452	NXvFVolrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfZZY9jUUN3ME2xMlg6ODd2IN88US=>	MW\TRW5ITVJ?
SK-MEL-2	NYHGUI1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfDTWM2OD1zLkmwNlcyKM7:TR?=	NXfk[5d[W0GQR1XS
OVCAR-5	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4K0NWlEPTB;MT65NFY4PSEQvF2=	NUTYR4ppW0GQR1XS
SNG-M	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP3U\|BKSzVyPUGuPVU5PThizszN	NH3lSJBUSU6JRWK=
A673	M4T6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X6N2lEPTB;MT65O\|UyPiEQvF2=	NXTTSZB4W0GQR1XS
L-428	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTaSWJKSzVyPUGuPVkyPzlizszN	MonqV2FPT0WU
KM-H2	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTYTWM2OD1{LkCxNFkh\|ryP	MmTzV2FPT0WU
MC-IXC	NI[xW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTE[FVpUUN3ME2yMlAzOjd\|IN88US=>	NUf1NpE4W0GQR1XS
COLO-678	NF;qPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LrO2lEPTB;Mj6wOFIxPyEQvF2=	MX7TRW5ITVJ?
MEL-JUSO	M4nEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTuTWM2OD1{LkC3PFUyKM7:TR?=	MnXLV2FPT0WU
HCC38	M4fxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7jO4dqUUN3ME2yMlA5PDN\|IN88US=>	M2D1[3NCVkeHUh?=
UACC-62	MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJwMEi4OVUh\|ryP	NGfoOWlUSU6JRWK=
OAW-42	M{L3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\rNoc6UUN3ME2yMlA6PzFzIN88US=>	M2LNXHNCVkeHUh?=
LB996-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXqwPVNCUUN3ME2yMlE{QDF5IN88US=>	MmjvV2FPT0WU
COR-L105	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jBfGlEPTB;Mj6xOlM4OyEQvF2=	M3zHUHNCVkeHUh?=
RCC10RGB	NVTKS4lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJwMUi1O\|Yh\|ryP	NVrKVXhTW0GQR1XS
A431	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm3enFqUUN3ME2yMlE6ODF7IN88US=>	NHHLeoZUSU6JRWK=
NCI-H292	M3XaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjL[Zo5UUN3ME2yMlI{QTVzIN88US=>	M4fO[XNCVkeHUh?=
SK-UT-1	NVTvN\|RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfkXWxKSzVyPUKuN\|MyQDRizszN	NIfP[4pUSU6JRWK=
PANC-08-13	NYP6UIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTJwM{OyN\|Uh\|ryP	MXnTRW5ITVJ?
ST486	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HITWlEPTB;Mj60NVA1QCEQvF2=	MXrTRW5ITVJ?
SJSA-1	NYrNdHR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHU[JlKSzVyPUKuOFEzPzFizszN	MX7TRW5ITVJ?
RKO	NFT3UZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTqTWM2OD1{LkSyNFI6KM7:TR?=	NYPkNIc5W0GQR1XS
NCI-H1793	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPETWM2OD1{LkS0NFI6KM7:TR?=	MlvkV2FPT0WU
639-V	NGPmcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\UcmlEPTB;Mj60OVM5OiEQvF2=	MWLTRW5ITVJ?
ES3	M3jyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:2eZpKSzVyPUKuOFk4OzdizszN	MVrTRW5ITVJ?
NCI-H1792	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M365RWlEPTB;Mj61OlgzPiEQvF2=	NWftdXJCW0GQR1XS
NCI-H1651	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjG[VFKSzVyPUKuOVgzOSEQvF2=	NIPadXNUSU6JRWK=
SN12C	MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJwNUi0PFch\|ryP	M1zoSHNCVkeHUh?=
COLO-679	NFntelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne0TWM2OD1{LkW4OlA2KM7:TR?=	NIHpc5RUSU6JRWK=
U-118-MG	M2qxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XsSmlEPTB;Mj61PFg4OiEQvF2=	M1z1O3NCVkeHUh?=
Ramos-2G6-4C10	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XHNGlEPTB;Mj62OFgxPyEQvF2=	MY\TRW5ITVJ?
HCT-15	M2jJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\zXHhKSzVyPUKuOlg4QTJizszN	MX7TRW5ITVJ?
MDA-MB-157	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TNNWlEPTB;Mj63NFc1PyEQvF2=	MVHTRW5ITVJ?
K5	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonoTWM2OD1{LkexPFQ2KM7:TR?=	M2HoTXNCVkeHUh?=
MKN45	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnvS2dKSzVyPUKuO\|M{PjZizszN	MkfzV2FPT0WU
DMS-273	M1zpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLJfZNvUUN3ME2yMlc2PjN{IN88US=>	NILtc2VUSU6JRWK=
C8166	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L1XmlEPTB;Mj63PFUyOyEQvF2=	MnWzV2FPT0WU
Calu-3	M3TYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTvWoVOUUN3ME2yMlc5QTZ7IN88US=>	MUjTRW5ITVJ?
SNB75	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rEcmlEPTB;Mj64PFU{PSEQvF2=	MW\TRW5ITVJ?
BFTC-905	NYDZNIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4izXmlEPTB;Mj65NFE6OSEQvF2=	MXXTRW5ITVJ?
C-4-II	NULpSZVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjt[GlKSzVyPUKuPVE{PTNizszN	NVPWPGtYW0GQR1XS
MS-1	NWD1Ro54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJwOU[3Olkh\|ryP	MnrKV2FPT0WU
A375	NXnoSYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTNwMEixPFQh\|ryP	M2GwdHNCVkeHUh?=
KYSE-70	NUn0enNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPRd3M2UUN3ME2zMlA5QDh{IN88US=>	NVLzdGx5W0GQR1XS
KYSE-510	NXXQNHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HwbGlEPTB;Mz6xNFk6PSEQvF2=	NYjEVlVYW0GQR1XS
LN-405	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33ie2lEPTB;Mz6xN\|UyQCEQvF2=	Ml74V2FPT0WU
BOKU	NV24d4d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTNwMUSyOVYh\|ryP	M3nwTHNCVkeHUh?=
TE-10	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEKweYNKSzVyPUOuNVc{PjJizszN	MkKwV2FPT0WU
MKN1	NYHFfWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLQVFRKSzVyPUOuNVg1QDNizszN	MkC0V2FPT0WU
M059J	NF7t[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1OxNmlEPTB;Mz6yNFE4OyEQvF2=	NEPxWIxUSU6JRWK=
GOTO	NHTLVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3IWpZSUUN3ME2zMlIzODN7IN88US=>	MkPCV2FPT0WU
DK-MG	NV;4VGlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon1TWM2OD1\|LkK1PVc3KM7:TR?=	NVi3dHV3W0GQR1XS
NCI-H727	NUfINolCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\Bb3NYUUN3ME2zMlI3PThizszN	MoXTV2FPT0WU
NB12	NX3hRmhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHBTWM2OD1\|LkOzNlI1KM7:TR?=	NEn2NmtUSU6JRWK=
DOK	M2\xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS2TWM2OD1\|LkO2NVg3KM7:TR?=	MWLTRW5ITVJ?
KYSE-410	NF;YbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILBUppKSzVyPUOuN\|YzQDdizszN	NG\BcnJUSU6JRWK=
AM-38	M3XtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zLZ2lEPTB;Mz6zPFA2OSEQvF2=	NHrGXm9USU6JRWK=
GR-ST	NWriVnBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWO5SlhwUUN3ME2zMlQ2PzN{IN88US=>	MVzTRW5ITVJ?
D-247MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrYSY9KSzVyPUOuOFgzPjNizszN	MXXTRW5ITVJ?
TE-8	M1vWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vNS2lEPTB;Mz60PVM{OyEQvF2=	MYrTRW5ITVJ?
LS-411N	NGezUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq4VGl7UUN3ME2zMlQ6Pjl{IN88US=>	M3vPZXNCVkeHUh?=
SK-MES-1	NGHLTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\je2lEPTB;Mz61OlQ{OyEQvF2=	MV;TRW5ITVJ?
SF295	M2XzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7PN5BKSzVyPUOuOlE2PTJizszN	MnS1V2FPT0WU
SK-MEL-30	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTLZYVmUUN3ME2zMlY2QTJzIN88US=>	MlnTV2FPT0WU
LB2241-RCC	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTBSWhKSzVyPUOuOlYzPiEQvF2=	NVzhVGE1W0GQR1XS
PC-14	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M130cmlEPTB;Mz62OlQ{PyEQvF2=	NY[1XFBkW0GQR1XS
EW-7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEG3eFVKSzVyPUOuOlc3QTNizszN	MVrTRW5ITVJ?
NMC-G1	NGHIcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT1TWM2OD1\|LkexPFM4KM7:TR?=	NXzyWnEyW0GQR1XS
TE-441-T	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkj1TWM2OD1\|LkezNFI5KM7:TR?=	NWHV[I5mW0GQR1XS
NCI-H1618	M1TWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTNwOEG4O\|Uh\|ryP	NYDlcVRpW0GQR1XS
PANC-03-27	M4W2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTlPXZKSzVyPUOuPFE6OTZizszN	MorLV2FPT0WU
NCI-H2228	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlWwTWM2OD1\|LkizNVI3KM7:TR?=	MWfTRW5ITVJ?
CAPAN-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTNwOEewNFkh\|ryP	M3nYb3NCVkeHUh?=
KLE	MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTNwOUC2O{DPxE1?	M3q5bHNCVkeHUh?=
Becker	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnX3TWM2OD1\|LkmyPFQ6KM7:TR?=	MX;TRW5ITVJ?
SK-PN-DW	NX\PSo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlztTWM2OD12LkC3PVc1KM7:TR?=	MYXTRW5ITVJ?
Hs-578-T	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTsTWM2OD12LkC4N\|A3KM7:TR?=	NInMenRUSU6JRWK=
RS4-11	M3ewWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHL2RZRKSzVyPUSuNVEzPTVizszN	NIfMWY5USU6JRWK=
D-502MG	NIT2fldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDmTWM2OD12LkG2PVk4KM7:TR?=	NYrQOGJqW0GQR1XS
GI-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[weHdKSzVyPUSuNlgzQTlizszN	M1jtdnNCVkeHUh?=
NCI-H209	MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn2c2ZKSzVyPUSuN\|M4QCEQvF2=	NGizVndUSU6JRWK=
SK-OV-3	M{LVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTRwNEixOFkh\|ryP	NF;TPHdUSU6JRWK=
LOUCY	NVHQcGU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvLfJhKSzVyPUSuOFg1OzJizszN	NFXXUFJUSU6JRWK=
NCI-H69	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTRwNUG3PVMh\|ryP	NH3RNHdUSU6JRWK=
SCC-9	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTRwNUOxO\|Ih\|ryP	MnzkV2FPT0WU
NCI-H526	NVnzZ2ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfkTWM2OD12LkW5Nlk{KM7:TR?=	MkLzV2FPT0WU
NCI-H2170	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPQZ\|k6UUN3ME20MlY3PzdzIN88US=>	NH7QfGpUSU6JRWK=
SR	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjuSoJHUUN3ME20MlcxODR6IN88US=>	M2r0fnNCVkeHUh?=
CMK	NFLVZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTRwN{KxNFEh\|ryP	M1LuO3NCVkeHUh?=
COLO-829	NWrKfm1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlL4TWM2OD12Lke3NFQ{KM7:TR?=	NVXlb2JbW0GQR1XS
HuO-3N1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTRwOEOyPFEh\|ryP	M4\0NHNCVkeHUh?=
5637	M2S0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULt[5ZMUUN3ME20MlkxPDh5IN88US=>	M4fEWnNCVkeHUh?=
A253	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\PfItYUUN3ME20Mlk4PzB6IN88US=>	NHq3R41USU6JRWK=
NB10	M2jKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nMRWlEPTB;NT6wO\|Q6PyEQvF2=	M1jKdnNCVkeHUh?=
SF539	NGHXRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HHeWlEPTB;NT6wPVk2QSEQvF2=	M1jyOHNCVkeHUh?=
HAL-01	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i5WmlEPTB;NT6xOFY1PSEQvF2=	NVuwNINuW0GQR1XS
MHH-ES-1	M{D0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTVwMU[5NlUh\|ryP	M2HIZ3NCVkeHUh?=
DEL	NGTNPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTVwMke1PFIh\|ryP	NGjnT2dUSU6JRWK=
NCI-H1299	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfCd5ZpUUN3ME21MlM2ODB5IN88US=>	NX3TW5dbW0GQR1XS
ChaGo-K-1	M4DOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4juVGlEPTB;NT6zOVExPyEQvF2=	MV\TRW5ITVJ?
HMV-II	NXXqOFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;wbIdVUUN3ME21MlM6PDNizszN	M33tXnNCVkeHUh?=
NB69	NGPRSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzPS49KSzVyPUWuN\|k3OzFizszN	NYLMOZJVW0GQR1XS
NCI-H1882	MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTVwNEOzOlQh\|ryP	MXnTRW5ITVJ?
SNU-475	NFPERopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3X3TGlEPTB;NT60O\|E4OSEQvF2=	M3O2WnNCVkeHUh?=
RXF393	NVqwc3E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX65Xo9yUUN3ME21MlQ5PDl2IN88US=>	M2O1WXNCVkeHUh?=
CAL-51	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW2TWM2OD13Lk[yPFU{KM7:TR?=	NUjNT\|h2W0GQR1XS
SW1573	NUmyXJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHUTWM2OD13Lk[zOVM1KM7:TR?=	NFzPPW5USU6JRWK=
GCT	NFfiWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi4e3pnUUN3ME21Mlc2QTJ7IN88US=>	MWjTRW5ITVJ?
COR-L88	MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjiTWM2OD13Lke2PFQ3KM7:TR?=	MWPTRW5ITVJ?
MDA-MB-134-VI	NWjCe4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjiTWM2OD13Lki3OVM3KM7:TR?=	NHS1cFdUSU6JRWK=
NB5	NX7Jd25lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTVwOUK0OEDPxE1?	MkS2V2FPT0WU
GMS-10	M2j1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTVwOU[4OlEh\|ryP	NWnBdXFCW0GQR1XS
CHP-212	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLCTWM2OD14LkS4NlY4KM7:TR?=	NH\IPIpUSU6JRWK=
TE-11	NY\tNopKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PPVmlEPTB;Nj61OVE5OiEQvF2=	NWTXWZMxW0GQR1XS
SW962	NYrsdW1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHntW4ZKSzVyPU[uOlU4PzRizszN	MV\TRW5ITVJ?
MZ2-MEL	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XyO2lEPTB;Nj64NlAyOSEQvF2=	NXv2OWhJW0GQR1XS
C-33-A	NHrH[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfvd2FKSzVyPU[uPVE3QDhizszN	MnT2V2FPT0WU
IGR-1	M4rheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTZwOUe4NlYh\|ryP	NWLKVIQ5W0GQR1XS
MOLT-4	M4LD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXv4e3lSUUN3ME23MlE2PDB4IN88US=>	MojNV2FPT0WU
NCI-H1650	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHxTWM2OD15LkK3NFQ3KM7:TR?=	MUDTRW5ITVJ?
AsPC-1	NEfTXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XjeGlEPTB;Nz6yPFYxPSEQvF2=	MnHzV2FPT0WU
SNU-C2B	M4HxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPaN3RRUUN3ME23MlI6PTdzIN88US=>	NGL2WZpUSU6JRWK=
MKN7	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nHS2lEPTB;Nz6zO\|I{PSEQvF2=	NGrJSW9USU6JRWK=
SW620	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTdwM{iyNFUh\|ryP	Mn;oV2FPT0WU
SK-MEL-28	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4H4S2lEPTB;Nz60NFc6QCEQvF2=	NGfVU\|JUSU6JRWK=
TE-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTdwNES5NFgh\|ryP	NFHXblJUSU6JRWK=
D-263MG	M4TafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2yXVBSUUN3ME23MlQ2PzZ{IN88US=>	M1n6T3NCVkeHUh?=
NCI-H1355	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi0SGFUUUN3ME23Mlc4ODJ7IN88US=>	M3jjU3NCVkeHUh?=
DSH1	NH\SUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTdwN{m3OlIh\|ryP	NIW3R2xUSU6JRWK=
NCI-H460	NWf4c2dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnSwTWM2OD16LkCwOlk1KM7:TR?=	M1nPNXNCVkeHUh?=
NCI-H1563	NIDQeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX21cmxNUUN3ME24MlA4PTB6IN88US=>	NHTzSW5USU6JRWK=
SW948	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlraTWM2OD16LkGwO\|Q1KM7:TR?=	M4XYR3NCVkeHUh?=
LK-2	M3zNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIP1coNKSzVyPUiuNVI5OzNizszN	MlOyV2FPT0WU
HT-1080	NWLSWpdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHO0T5pKSzVyPUiuNVMyPzVizszN	M1PITXNCVkeHUh?=
NCI-H441	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jVVmlEPTB;OD6xPVMh\|ryP	NFLlR5pUSU6JRWK=
HSC-4	M1LhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jZSWlEPTB;OD6yPFczKM7:TR?=	NVjHXXJ6W0GQR1XS
LXF-289	M4Cxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7jTWM2OD16LkO1PVQ{KM7:TR?=	MW\TRW5ITVJ?
MRK-nu-1	NH3JN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHrTWM2OD16LkO2N\|A1KM7:TR?=	MVXTRW5ITVJ?
no-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2e5XmlEPTB;OD60O\|E{OyEQvF2=	NGrCcHpUSU6JRWK=
SNU-387	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\XfHBKSzVyPUiuOlMzPDZizszN	NEjzR5JUSU6JRWK=
Detroit562	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHS1cFJKSzVyPUiuO\|U1PTVizszN	MkT0V2FPT0WU
SW954	NWnJN\|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXYcIxKSzVyPUiuO\|Y5OzJizszN	M2Hv[XNCVkeHUh?=
P12-ICHIKAWA	NEHUR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXoWFhKSzVyPUiuO\|g6PCEQvF2=	MWXTRW5ITVJ?
TE-9	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRThwOEGwOlIh\|ryP	MUnTRW5ITVJ?
NB13	NHPoZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTUTWM2OD16LkizO\|k3KM7:TR?=	NXfBOoNSW0GQR1XS
BPH-1	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRThwOEWwPFEh\|ryP	NFLPRllUSU6JRWK=
KMOE-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof4TWM2OD16Lki3PFkzKM7:TR?=	NGPE[WxUSU6JRWK=
RPMI-8402	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHZbHNmUUN3ME24Mlg6QTJ4IN88US=>	MljnV2FPT0WU
OVCAR-3	M4DCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2njVGlEPTB;OD65O\|c{OiEQvF2=	NUXBfmwzW0GQR1XS
NCI-H2196	NWfrfJFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRThwOUi2NFYh\|ryP	NF\JcllUSU6JRWK=
MZ7-mel	NF60VoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTlwMEO0OkDPxE1?	MYjTRW5ITVJ?
GP5d	M{LHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\ITWM2OD17LkC2N\|E{KM7:TR?=	MWfTRW5ITVJ?
NCI-N87	NUfnVJQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfGWY5iUUN3ME25MlQ1PzNzIN88US=>	NYXTN\|FLW0GQR1XS
EW-16	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvSUllKSzVyPUmuOFQ5PDhizszN	NGLQWGNUSU6JRWK=
Calu-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnEU2xKSzVyPUmuOFk4ODNizszN	MVnTRW5ITVJ?
LC4-1	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofxTWM2OD17Lk[yOVch\|ryP	MWfTRW5ITVJ?
CCRF-CEM	M3HOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnYTWM2OD17Lk[4O\|Y3KM7:TR?=	M3j4[XNCVkeHUh?=
BC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTlwN{i5PUDPxE1?	NXuzc5FDW0GQR1XS
NCI-SNU-16	NE\2[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL6fHZKSzVyPUmuO\|k1QTVizszN	MmnlV2FPT0WU
NCI-H28	NXLkPHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fpSmlEPTB;OT64OFk{OyEQvF2=	MlXnV2FPT0WU
SBC-1	NInacJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\tTmlEPTB;MUCuNFczKM7:TR?=	MmmxV2FPT0WU
TUR	NYThTpRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z1dmlEPTB;MUCuNVY2PyEQvF2=	MlLrV2FPT0WU
MDA-MB-231	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHRXXA2UUN3ME2xNE4zOTF2IN88US=>	NEDlOWNUSU6JRWK=
C3A	M1XDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTFyLkOxO\|kh\|ryP	NF;aZoVUSU6JRWK=
SW1990	NITO[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK5eJlNUUN3ME2xNE4{OjhizszN	NXOybnhpW0GQR1XS
NCI-H1993	M4jrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LuPWlEPTB;MUCuOVY6OyEQvF2=	NFvN[WJUSU6JRWK=
SK-CO-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnCeHpKSzVyPUGwMlc4PyEQvF2=	MWrTRW5ITVJ?
OAW-28	M3XRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFyLkm4PFgh\|ryP	M{TRcnNCVkeHUh?=
HN	NWHiZZRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTFzLkGxN\|Eh\|ryP	NH;jVYhUSU6JRWK=
NCI-H1304	NF\6cFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfsXWdKSzVyPUGxMlE2PzZizszN	M2TTPXNCVkeHUh?=
Daoy	NWXiT5poT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGSwbGRKSzVyPUGxMlQ{OzZizszN	M3vDPHNCVkeHUh?=
VA-ES-BJ	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXZR4lKSzVyPUGxMlcyQTVizszN	MYTTRW5ITVJ?
MCF7	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTPTWM2OD1zMT64NVI3KM7:TR?=	NXvL[mVlW0GQR1XS
VM-CUB-1	NFzJXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFzLkmwPVEh\|ryP	NHS4UIRUSU6JRWK=
IPC-298	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTFzLkmzPFMh\|ryP	MYTTRW5ITVJ?
NCI-H2126	M{Lhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPybXNKSzVyPUGyMlAzOThizszN	NF61Z49USU6JRWK=
OVCAR-8	M1n4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfiNIUzUUN3ME2xNk4yOTRzIN88US=>	M2LHOXNCVkeHUh?=
SJRH30	M1nhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm[2TWM2OD1zMj6yNlk6KM7:TR?=	MlvsV2FPT0WU
DMS-53	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi1Z5FKSzVyPUGyMlI3PDlizszN	MmrBV2FPT0WU
NCI-H322M	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTF{LkOzOVch\|ryP	NU\X[VlnW0GQR1XS
RVH-421	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jZdmlEPTB;MUKuOFkxPCEQvF2=	MmfhV2FPT0WU
Raji	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFe5NYFKSzVyPUGyMlYyPCEQvF2=	MVLTRW5ITVJ?
MDA-MB-415	M124Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzvSZpKSzVyPUGyMlY1PDRizszN	M2LoSnNCVkeHUh?=
EFE-184	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTF{LkexNFYh\|ryP	NIS1NIFUSU6JRWK=
BFTC-909	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTF{LkmyOFch\|ryP	NFLG[HlUSU6JRWK=
BHY	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjjTWM2OD1zMz6zN\|kh\|ryP	MmrQV2FPT0WU
YKG-1	NHryWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPKTWM2OD1zMz6zO\|Q6KM7:TR?=	MUTTRW5ITVJ?
EW-3	NXrKdYhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPaTWM2OD1zMz63NVY{KM7:TR?=	MVjTRW5ITVJ?
HCC1143	NWLXb4k3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17EZmlEPTB;MUOuO\|Q{PyEQvF2=	NXG3c\|dRW0GQR1XS
REH	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknrTWM2OD1zMz64PVgzKM7:TR?=	M4X3W3NCVkeHUh?=
CESS	M2HTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK5TXBKSzVyPUGzMlk1QDlizszN	MnzSV2FPT0WU
EFM-19	M3nCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoqzTWM2OD1zND6xNVEzKM7:TR?=	NVz0[IQ{W0GQR1XS
U031	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnkTWM2OD1zND60NFg2KM7:TR?=	NFL3dphUSU6JRWK=
ES1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLRNmI1UUN3ME2xOE41QDVzIN88US=>	MVTTRW5ITVJ?
HSC-3	NIrBXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHS4clFKSzVyPUG0MlYzOTVizszN	NW\me\|d7W0GQR1XS
LOXIMVI	NUjEVItzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjnfJBKSzVyPUG0MlcxPjhizszN	NGfxVXBUSU6JRWK=
A388	NV7tRo94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fVZmlEPTB;MUSuO\|U2PiEQvF2=	MXjTRW5ITVJ?
KP-N-YS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vaPGlEPTB;MUSuO\|c{KM7:TR?=	Mof4V2FPT0WU
Capan-2	NFTOfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXu4TmV4UUN3ME2xOE44QDZizszN	MYDTRW5ITVJ?
SKG-IIIa	M2Oxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT3TWM2OD1zND64PFYzKM7:TR?=	M3jheHNCVkeHUh?=
HEL	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnSOmtOUUN3ME2xOE45QTl5IN88US=>	NGHJOY9USU6JRWK=
BEN	NG\1d\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTF2Lkm3OlYh\|ryP	NWm2ZYVoW0GQR1XS
MC116	M2nEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW4TWM2OD1zNT6xOVk6KM7:TR?=	MVjTRW5ITVJ?
IGROV-1	NWDWU3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTDTWM2OD1zNT6yN\|E4KM7:TR?=	M{XiW3NCVkeHUh?=
NCI-H1648	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjTTXI5UUN3ME2xOU42OzB3IN88US=>	NIjU[VdUSU6JRWK=
ABC-1	NHTrSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjXTWM2OD1zNT64NFM{KM7:TR?=	MWHTRW5ITVJ?
EW-18	NYT5dnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDtTWM2OD1zNT65PVc6KM7:TR?=	MlX4V2FPT0WU
BC-3	NXz4TZJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTF4LkC1OlIh\|ryP	MmDLV2FPT0WU
NCI-H1437	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnSUlFKSzVyPUG2MlA3PjdizszN	MknUV2FPT0WU
SCC-15	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELBfFlKSzVyPUG2MlI5OjVizszN	Mmi1V2FPT0WU
TT	NXPnPXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWWzUot[UUN3ME2xOk42QDh6IN88US=>	MlT1V2FPT0WU
KINGS-1	NXL4XW9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7PTWM2OD1zNj64Nlc{KM7:TR?=	MY\TRW5ITVJ?
C32	M{TxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\2NY1KSzVyPUG2Mlk4OTdizszN	NUnyXFRDW0GQR1XS
SBC-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF5LkG0O\|kh\|ryP	NIXXbolUSU6JRWK=
NB1	M{DVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTF5LkOxPFgh\|ryP	MY\TRW5ITVJ?
EB-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPUTWM2OD1zNz61O\|Yh\|ryP	NFnPVllUSU6JRWK=
NCI-H748	M1voWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIqzdHlKSzVyPUG3MlcxOzVizszN	M1yxRXNCVkeHUh?=
IST-SL1	NGjiSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofRTWM2OD1zNz63OVI3KM7:TR?=	MWPTRW5ITVJ?
WM-115	NIPrb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LvO2lEPTB;MUeuPFA5PSEQvF2=	MkfGV2FPT0WU
NCI-H226	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrGTWM2OD1zNz65OVQ3KM7:TR?=	NFLyUllUSU6JRWK=
CAL-33	M1vz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXrNYlKSzVyPUG4MlI4QDFizszN	MmPXV2FPT0WU
SCC-4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[5TWM2OD1zOD6zNlI6KM7:TR?=	MlruV2FPT0WU
RMG-I	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3Jc5R{UUN3ME2xPE43QTR5IN88US=>	M3TNWnNCVkeHUh?=
KOSC-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTF6Lke3OFYh\|ryP	M3z0ZnNCVkeHUh?=
A2058	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHsUm1LUUN3ME2xPE45OjV3IN88US=>	Mn;rV2FPT0WU
HCC70	MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TuNWlEPTB;MUmuN\|g6PCEQvF2=	NXT4OJl4W0GQR1XS
C2BBe1	NWjMNohsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXoTWM2OD1zOT60NVQ5KM7:TR?=	NYH3c4tZW0GQR1XS
NCI-H650	NWnSXY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPxfpZ[UUN3ME2xPU42QDl7IN88US=>	NWrPXHhnW0GQR1XS
CAL-72	NFjMVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjR[\|ZUUUN3ME2xPU43PzN5IN88US=>	MlnKV2FPT0WU
L-363	M3;Gd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXFTWM2OD1{MD6wNlEzKM7:TR?=	NXW0d4RLW0GQR1XS
SNU-423	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJyLkGwOFMh\|ryP	NVHkUnBvW0GQR1XS
PLC-PRF-5	M3zafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTJyLkO5NFYh\|ryP	NILaclBUSU6JRWK=
SW1463	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPmb4w2UUN3ME2yNE41PTJ3IN88US=>	NE\4fHFUSU6JRWK=
769-P	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHoTHdKSzVyPUKwMlY4PjlizszN	NFyyNoVUSU6JRWK=
DMS-79	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\SNohQUUN3ME2yNE45PDlizszN	NWPzXphIW0GQR1XS
Saos-2	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLhTWM2OD1{MD65OVU3KM7:TR?=	MY\TRW5ITVJ?
CHP-126	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInG[49KSzVyPUKxMlQ1PjJizszN	NWTJcoFqW0GQR1XS
SW837	M{XS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLjTZpKSzVyPUKxMlQ6OzlizszN	M3PEZXNCVkeHUh?=
SHP-77	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLF[pBKSzVyPUKxMlYyOjJizszN	MXjTRW5ITVJ?
DB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTMXXRKSzVyPUKxMlYyPDJizszN	Moi2V2FPT0WU
ES5	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[z[lRKSzVyPUKxMlY5PjRizszN	NFy1eIpUSU6JRWK=
COR-L23	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJzLkiwOVEh\|ryP	NVO2ZVZGW0GQR1XS
KU-19-19	NWLwXWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJzLki5PFIh\|ryP	MYPTRW5ITVJ?
T84	NHvKWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1yxeGlEPTB;MkGuPVgyQSEQvF2=	MkXIV2FPT0WU
NCI-H630	NEHYbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTGW3ZKSzVyPUKyMlU{PjNizszN	M3;t[nNCVkeHUh?=
LU-165	M{frbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTBSWVKSzVyPUKyMlU2PCEQvF2=	M1\xUHNCVkeHUh?=
COLO-792	NEXVcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLmTWM2OD1{Mj63NVEyKM7:TR?=	NUHWeo9ZW0GQR1XS
CAL-62	M1nVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jyNGlEPTB;MkKuO\|UyPyEQvF2=	NWfifplIW0GQR1XS
HCE-T	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\IU3NKSzVyPUKyMlg3ODZizszN	NHzxcHFUSU6JRWK=
BB65-RCC	M4TZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJ\|LkCzOFQh\|ryP	MWLTRW5ITVJ?
SiHa	M3j6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjLVVFKSzVyPUKzMlM6PjhizszN	NVHye2prW0GQR1XS
NCI-H2081	NFT2b2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PEcGlEPTB;MkSuNFY1OSEQvF2=	M2rBdHNCVkeHUh?=
U251	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDSTWM2OD1{ND6wOlY5KM7:TR?=	M4XyNnNCVkeHUh?=
LoVo	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJ2LkmyPFIh\|ryP	M4TiNHNCVkeHUh?=
GCIY	NGHPNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3HNVZvUUN3ME2yOU4zQDd5IN88US=>	MV7TRW5ITVJ?
NUGC-3	NYPHXnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfQTWM2OD1{NT6zN\|E3KM7:TR?=	MmDxV2FPT0WU
LNCaP-Clone-FGC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLOc45KSzVyPUK1MlM1QThizszN	M3flS3NCVkeHUh?=
PA-1	NVjaemxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{n5NmlEPTB;MkWuOlg{OyEQvF2=	MV3TRW5ITVJ?
OE33	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37mfGlEPTB;MkWuOlg2OyEQvF2=	MUjTRW5ITVJ?
HT-29	M4rQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXyTVdKSzVyPUK1Mlc5PzlizszN	MV3TRW5ITVJ?
RCM-1	NIHY[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX3TWM2OD1{NT65OlU3KM7:TR?=	M4Hx[nNCVkeHUh?=
NCI-H1522	NYLjN41CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHXTWM2OD1{NT65PVEyKM7:TR?=	MlrmV2FPT0WU
LB373-MEL-D	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXR[ZpKSzVyPUK2MlE4ODhizszN	NXLvfFVYW0GQR1XS
NCI-H1436	NF2zSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPWR5NvUUN3ME2yOk4zPzN6IN88US=>	Mlf5V2FPT0WU
COLO-824	NETTNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3ZVVVtUUN3ME2yOk41ODB{IN88US=>	MnzZV2FPT0WU
CP50-MEL-B	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ4LkW2O\|Uh\|ryP	M1naS3NCVkeHUh?=
EGI-1	NXrvRYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13QOGlEPTB;MkeuNlY6QCEQvF2=	NVvzcGFZW0GQR1XS
LAN-6	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPu[VVbUUN3ME2yO{4{PTl6IN88US=>	MmHoV2FPT0WU
GAK	NFTUTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXRTWM2OD1{Nz60NlI2KM7:TR?=	Mo\DV2FPT0WU
MDA-MB-175-VII	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJ5LkWwOVMh\|ryP	NVLpVWFQW0GQR1XS
JVM-2	NInSVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHjTWM2OD1{Nz62OlIzKM7:TR?=	NVHjZlFUW0GQR1XS
UACC-257	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJ5Lk[4O\|gh\|ryP	MVvTRW5ITVJ?
SW1783	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\zdlBKSzVyPUK3Mlc4QDNizszN	Ml:zV2FPT0WU
HT-3	NYX4W\|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq5XmxDUUN3ME2yPE4zOTZ4IN88US=>	MmrJV2FPT0WU
RL	NIrPOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHyyNpVKSzVyPUK4MlU6OTFizszN	MXTTRW5ITVJ?
TK10	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\2ZWNKSzVyPUK4MlY2OzVizszN	MmrIV2FPT0WU
HT55	NVrvUGJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTrTYl2UUN3ME2yPU4xPTZ3IN88US=>	NGW4T5NUSU6JRWK=
BT-20	M3zNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n6Z2lEPTB;MkmuNFU5PiEQvF2=	MX\TRW5ITVJ?
TGBC24TKB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP5TWM2OD1{OT6xPFMyKM7:TR?=	MoX1V2FPT0WU
HSC-2	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTJ7LkOwNFEh\|ryP	MVrTRW5ITVJ?
COLO-205	M4ntdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTJ7LkO5OFQh\|ryP	NV\6U2hUW0GQR1XS
GT3TKB	M1;Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TtXGlEPTB;MkmuOlg4PyEQvF2=	M1ezT3NCVkeHUh?=
T47D	NVjCVYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jZ[mlEPTB;MkmuPFU5OiEQvF2=	NXrVc3NSW0GQR1XS
OMC-1	M{TpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPPTWM2OD1\|MD6xPVE6KM7:TR?=	M{naSnNCVkeHUh?=
PFSK-1	NX7XVolYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkW3TWM2OD1\|MT6yOlU6KM7:TR?=	NIXkSJVUSU6JRWK=
JEG-3	M4nPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[4V4dKSzVyPUOxMlM2PjFizszN	NYTIWoRoW0GQR1XS
RD	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnId\|YyUUN3ME2zNU42OTF3IN88US=>	MW\TRW5ITVJ?
NCI-H64	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfmXZFLUUN3ME2zNk41OTd7IN88US=>	MYLTRW5ITVJ?
DMS-114	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfkd4lKSzVyPUOyMlQyQDJizszN	MmHtV2FPT0WU
NCI-H661	M2\zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTN{Lk[1NFEh\|ryP	M1\kOHNCVkeHUh?=
CAL-148	M1TONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITXTo1KSzVyPUOyMlY3PjVizszN	Mnu3V2FPT0WU
HuP-T3	NFrVc\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO0SHpKSzVyPUOyMlk{OzhizszN	NFKxUnNUSU6JRWK=
ES4	M4nOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTN\|LkG3NFUh\|ryP	NIL4OpJUSU6JRWK=
Ca9-22	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIK2SG5KSzVyPUOzMlQ3ODFizszN	NVP1W5dJW0GQR1XS
LP-1	NYTzUGdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfaZlBKSzVyPUO0MlA6KM7:TR?=	NIXDcWZUSU6JRWK=
AU565	M{OwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPUR3FKSzVyPUO0MlUxPjlizszN	MnuyV2FPT0WU
MDA-MB-453	M3zvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;WTWM2OD1\|NT6xOFI3KM7:TR?=	NXfh[WNkW0GQR1XS
SNU-C1	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjvTWM2OD1\|NT6xO\|Eh\|ryP	MWPTRW5ITVJ?
SW13	NFz2em1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PQVmlEPTB;M{WuOFA4PiEQvF2=	MWDTRW5ITVJ?
NCI-H2122	MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofyTWM2OD1\|NT61OVk5KM7:TR?=	M3n5dnNCVkeHUh?=
NCI-H1395	NX7Le2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCxOldDUUN3ME2zOU43PjlzIN88US=>	NGLUZWVUSU6JRWK=
J-RT3-T3-5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXmyblJzUUN3ME2zOk4xOjl2IN88US=>	NFXEcplUSU6JRWK=
COR-L279	MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTN4LkG5PFEh\|ryP	NEL1cY9USU6JRWK=
ATN-1	NEXHSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILobWZKSzVyPUO2Mlg2OTZizszN	NVjvUmRDW0GQR1XS
HCC2998	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPzTWM2OD1\|Nj64OVcyKM7:TR?=	NWHuVWR{W0GQR1XS
UM-UC-3	NF\leGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPjOFczUUN3ME2zOk45Pjd3IN88US=>	NXjaZVY2W0GQR1XS
DV-90	NEjibIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi2ZYNvUUN3ME2zOk46ODZ5IN88US=>	M4X2WnNCVkeHUh?=
ES8	M4jWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Xxd2lEPTB;M{[uPVMyQCEQvF2=	NEPVeHFUSU6JRWK=
YAPC	M2DYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HIU2lEPTB;M{[uPVY2PCEQvF2=	MV\TRW5ITVJ?
HCC1599	NGXjUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzw[4JnUUN3ME2zO{4yPjF6IN88US=>	NGTFNIlUSU6JRWK=
UMC-11	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrBUZoyUUN3ME2zO{4zPTB\|IN88US=>	NG\vWplUSU6JRWK=
THP-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHO4W4RKSzVyPUO3MlI5PjhizszN	NUj0WWxnW0GQR1XS
OCUB-M	NX\HSGw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDZfpVKUUN3ME2zO{4zQDlzIN88US=>	M{LFRnNCVkeHUh?=
NCI-H1693	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrqW5pKSzVyPUO3MlMzOzNizszN	MoXqV2FPT0WU
NCI-H345	NF\ufYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTN5LkO2NlQh\|ryP	NH\tbXdUSU6JRWK=
COLO-800	M1z1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTN5LkW2O{DPxE1?	MVrTRW5ITVJ?
COLO-320-HSR	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[y[2FwUUN3ME2zPE4{PDl{IN88US=>	M3;ubXNCVkeHUh?=
NCI-H596	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHJTWM2OD1\|OD60OFg6KM7:TR?=	NYC5[\|FHW0GQR1XS
NCI-H187	M1[1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2S4UGlEPTB;M{iuO\|M1PCEQvF2=	NVLXN2h3W0GQR1XS
ECC4	M2WwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPCeGZwUUN3ME2zPU4xQDF2IN88US=>	MVXTRW5ITVJ?
KP-4	M3jadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPiTWM2OD1\|OT6xNlM2KM7:TR?=	MlzjV2FPT0WU
NCI-H2227	M{LCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXXNVVKSzVyPUO5MlM6PDlizszN	Mn3MV2FPT0WU
22RV1	NIXxPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlWzTWM2OD1\|OT64N\|k5KM7:TR?=	MWPTRW5ITVJ?
SAS	M2G2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n4TWlEPTB;NECuNFk3KM7:TR?=	NHzhTVZUSU6JRWK=
PANC-10-05	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv0UI9KSzVyPUSwMlE5OjhizszN	NYDyeolTW0GQR1XS
MDA-MB-468	NH;PPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGixXZlKSzVyPUSwMlU{PDZizszN	Ml\5V2FPT0WU
RPMI-7951	NWDBbpZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnYWGFWUUN3ME20NU4zODd3IN88US=>	MUXTRW5ITVJ?
BB49-HNC	NWfsd\|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LPTWlEPTB;NEGuNlE4QSEQvF2=	MWrTRW5ITVJ?
23132-87	M3LTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRzLkK3N\|Ih\|ryP	M1fL[nNCVkeHUh?=
HCC1569	NX61SJJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVj1[5k4UUN3ME20NU4zQDh3IN88US=>	NIrxUphUSU6JRWK=
CP66-MEL	Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorOTWM2OD12Mj6xPFg3KM7:TR?=	NGnYXlRUSU6JRWK=
K-562	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzJTWM2OD12Mj6yPFU1KM7:TR?=	NW\iWmZtW0GQR1XS
OCI-AML2	NWrLNIFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXlTWM2OD12Mj64PVc1KM7:TR?=	MlPHV2FPT0WU
SW756	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4myV2lEPTB;NEOuNFM5QCEQvF2=	NXHFXHo5W0GQR1XS
M14	NWn1[IJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH6OnVFUUN3ME20N{4{OTh7IN88US=>	MlLXV2FPT0WU
NCI-H1623	M{j4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXGye41WUUN3ME20N{41PjRizszN	NGC5SXNUSU6JRWK=
KNS-81-FD	NXq2eJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3ldFZKSzVyPUSzMlc3OiEQvF2=	MUDTRW5ITVJ?
TGBC1TKB	M3XDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljaTWM2OD12Mz65NFk6KM7:TR?=	MYnTRW5ITVJ?
RERF-LC-MS	NYrxSXByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofFTWM2OD12Mz65NlgyKM7:TR?=	NX75XopIW0GQR1XS
PC-3	NEH1V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTR2LkSzOFch\|ryP	NHfqb49USU6JRWK=
HuP-T4	NV\4PZVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTR2LkS0O\|Qh\|ryP	Ml3MV2FPT0WU
NCI-H510A	NIriWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofvTWM2OD12ND63NFgh\|ryP	NELYb2tUSU6JRWK=
LB2518-MEL	MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvnNnhLUUN3ME20OE44QTN5IN88US=>	MlLJV2FPT0WU
TE-5	M4r4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVu3ZodmUUN3ME20OU46PThzIN88US=>	M2SzNnNCVkeHUh?=
EW-24	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\WVYRKSzVyPUS2MlE4OjNizszN	NF\pb25USU6JRWK=
LB647-SCLC	NV2ySJAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfFTWM2OD12Nj6yNVU2KM7:TR?=	M13jV3NCVkeHUh?=
NCI-H524	NED5S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLscI5iUUN3ME20Ok44OTh3IN88US=>	M{\KbXNCVkeHUh?=
EW-11	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTR4LkmzO\|Mh\|ryP	NID2fGVUSU6JRWK=
KALS-1	M{G0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3BXWxrUUN3ME20O{4zODZ4IN88US=>	MnvtV2FPT0WU
BT-474	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUezN5BwUUN3ME20O{41OjF4IN88US=>	MkHsV2FPT0WU
SK-N-AS	M{TRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTR5Lki4PEDPxE1?	MXnTRW5ITVJ?
HCC2157	NGPxbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTR6LkC3OkDPxE1?	NE\3eWxUSU6JRWK=
HCC1954	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3GOZgzUUN3ME20PE4yPzB2IN88US=>	NH2zcYFUSU6JRWK=
FADU	M3H1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTR6LkOwN\|Eh\|ryP	M4CyS3NCVkeHUh?=
S-117	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTR6LkO4NVUh\|ryP	M3PodHNCVkeHUh?=
LS-1034	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHhN5B1UUN3ME20PE44ODZ5IN88US=>	MVzTRW5ITVJ?
CAMA-1	NX;uNGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXG1Oph7UUN3ME20PU42PTR\|IN88US=>	NVHJXIw2W0GQR1XS
LU-134-A	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnPOolFUUN3ME20PU45ODh3IN88US=>	M2X6cXNCVkeHUh?=
NCI-H1838	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTR7LkiwPFch\|ryP	NHW4OnJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	- Collapse Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	November 22 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571, CGP-57148B) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib Mesylate (STI571) induces autophagy.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406, NS-187) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate (HQP1351) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)